PURPOSE: The use of hepatitis B core antibody (HBcAb)-positive grafts is increasing, especially where hepatitis B is endemic. However, this remains controversial because of the risk of development of de novo HBV infection. METHODS: We collected information obtained between January 2000 and December 2012 and retrospectively analyzed data on 187 HBsAg-negative donors and recipients were analyzed retrospectively. De novo HBV infection was defined as development of HBsAg positivity with or without detection of HBV DNA. RESULTS: Forty patients (21.4%) received HBcAb-positive grafts. Survival rate did not differ by donor HBcAb status (P = 0.466). De novo HBV infection occurred in five patients (12.5%) who were not treated with anti-HBV prophylaxis, and was significantly more prevalent in hepatitis B surface antibody (HBsAb)- and HBcAb-negative than HBsAb- and HBcAb-positive recipients (50% vs. 4.2%, P = 0.049). All patients except one were treated with entecavir with/without antihepatitis B immunoglobulin and four were negative in terms of HBV DNA seroconversion. No patient died. CONCLUSION: HBcAb-positive grafts are safe without survival difference. However, the risk of de novo hepatitis B virus infection was significantly increased in HBsAb- and HBcAb-negative recipients. All patients were successfully treated even after recurrence.
PURPOSE: The use of hepatitis B core antibody (HBcAb)-positive grafts is increasing, especially where hepatitis B is endemic. However, this remains controversial because of the risk of development of de novo HBV infection. METHODS: We collected information obtained between January 2000 and December 2012 and retrospectively analyzed data on 187 HBsAg-negative donors and recipients were analyzed retrospectively. De novo HBV infection was defined as development of HBsAg positivity with or without detection of HBV DNA. RESULTS: Forty patients (21.4%) received HBcAb-positive grafts. Survival rate did not differ by donor HBcAb status (P = 0.466). De novo HBV infection occurred in five patients (12.5%) who were not treated with anti-HBV prophylaxis, and was significantly more prevalent in hepatitis B surface antibody (HBsAb)- and HBcAb-negative than HBsAb- and HBcAb-positive recipients (50% vs. 4.2%, P = 0.049). All patients except one were treated with entecavir with/without antihepatitis B immunoglobulin and four were negative in terms of HBV DNA seroconversion. No patient died. CONCLUSION: HBcAb-positive grafts are safe without survival difference. However, the risk of de novo hepatitis B virus infection was significantly increased in HBsAb- and HBcAb-negative recipients. All patients were successfully treated even after recurrence.
Entities:
Keywords:
Hepatitis B antibodies; Liver transplantation; Prognosis; de novo hepatitis B
Authors: I Villamil; A González-Quintela; A Aguilera; S Tomé; E Otero; F J Castroagudín; E Varo Journal: Am J Gastroenterol Date: 2004-04 Impact factor: 10.864
Authors: M Prieto; M D Gómez; M Berenguer; J Córdoba; J M Rayón; M Pastor; A García-Herola; D Nicolás; D Carrasco; J F Orbis; J Mir; J Berenguer Journal: Liver Transpl Date: 2001-01 Impact factor: 5.799
Authors: Matthew S Chang; Sonja K Olsen; Elsa M Pichardo; Jessica B Stiles; Lori Rosenthal-Cogan; William D Brubaker; James V Guarrera; Jean C Emond; Robert S Brown Journal: Transplantation Date: 2013-04-15 Impact factor: 4.939
Authors: Guy N Brock; Farida Mostajabi; Nicole Ferguson; Christopher J Carrubba; Mary Eng; Joseph F Buell; Michael R Marvin Journal: Transpl Int Date: 2011-03-15 Impact factor: 3.782
Authors: Mario Angelico; Alessandra Nardi; Tania Marianelli; Lucio Caccamo; Renato Romagnoli; Giuseppe Tisone; Antonio D Pinna; Alfonso W Avolio; Stefano Fagiuoli; Patrizia Burra; Mario Strazzabosco; Alessandro Nanni Costa Journal: J Hepatol Date: 2012-11-28 Impact factor: 25.083
Authors: A Celebi Kobak; Z Karasu; M Kilic; T Ozacar; F Tekin; F Gunsar; G Ersoz; Y Yuzer; Y Tokat Journal: Transplant Proc Date: 2007-06 Impact factor: 1.066
Authors: Romina Salpini; Lorenzo Piermatteo; Upkar Gill; Arianna Battisti; Francesca Stazi; Tania Guenci; Sara Giannella; Valentina Serafini; Patrick T F Kennedy; Carlo Federico Perno; Valentina Svicher; Marco Ciotti Journal: Med Microbiol Immunol Date: 2017-04-11 Impact factor: 3.402